8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Apr 14, 2026·SEC
Aligos Therapeutics, Inc.(ALGS)Earnings, Financials & Key Ratios
ALGS•NASDAQ
$6.09
Price updated Jul 7, 2026
AboutAligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.Show more
- Revenue$2M-44.6%
- EBITDA-$87M-0.6%
- Net Income-$24M+81.6%
- EPS (Diluted)-2.45+88.3%
- Gross Margin57.46%-42.5%
- EBITDA Margin-3982.39%-81.6%
- Operating Margin-4024.93%-78.1%
- Net Margin-1106.72%+66.7%
- ROE-196.92%+52.6%
ALGS Price & Volume
Aligos Therapeutics, Inc. (ALGS) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Aligos Liquidity Position
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent capital dilution risk
Key Thesis Takeaways
- Aligos Therapeutics faces a precarious financial outlook as its clinical-stage pipeline continues to generate significant losses, with R&D expenses reaching $23.4M in 2026Q1 against minimal revenue.
- The company's reliance on lumpy, milestone-based income creates extreme volatility, while the erosion of total assets from $151.5M in 2023Q4 to $64.6M in 2026Q1 highlights a critical need for non-dilutive capital.
- Investors should remain cautious as the firm's inability to achieve operating leverage, evidenced by a -9.5% operating margin in 2026Q1, suggests that ongoing development costs will continue to outpace commercial progress.
Verdict Logic
the company's cash position has dwindled to $30.2M as of 2026Q1, creating an imminent risk of dilutive financing to sustain its high-cost clinical development programs.
ALGS Growth Metrics
Aligos Therapeutics, Inc. (ALGS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-46.03%
TTM43.88%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-69.59%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM50.2%
Return on Capital
10 Years-70.28%
5 Years-89.8%
3 Years-108.85%
Last Year-152.15%
Peers Comparison
Key metrics vs top competitors for Aligos Therapeutics, Inc. (ALGS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.09 | $37.69M | -2.49 | -44.59% | -1106.72% | -196.92% | — | |
| $86.97 | $12.25B | -7128.69 | 23258.15% | -48.38% | -55.09% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $136.36 | $169.3B | 20.11 | 2.39% | 30.99% | 42.33% | — | |
| $522.25 | $132.84B | 34.09 | 9.57% | 35.4% | 23.93% | — |
Compare ALGS vs Peers
Aligos Therapeutics, Inc. (ALGS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ALGS SEC Filings & Documents
Aligos Therapeutics, Inc. (ALGS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ALGS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ALGS Frequently Asked Questions
Aligos Therapeutics, Inc. (ALGS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Aligos Therapeutics, Inc.'s revenue?
Aligos Therapeutics, Inc. (ALGS) reported $4.7M in revenue for fiscal year 2025.
How fast is Aligos Therapeutics, Inc. growing?
Aligos Therapeutics, Inc. (ALGS) saw revenue decline by 44.6% over the past year.
Is ALGS profitable?
Aligos Therapeutics, Inc. (ALGS) reported a net loss of $90.3M for fiscal year 2025.
Dividend & Returns
What is ALGS's return on equity?
Aligos Therapeutics, Inc. (ALGS) has a return on equity (ROE) of -196.9%. Negative ROE indicates the company is unprofitable.
What is Aligos Therapeutics, Inc.'s free cash flow?
Aligos Therapeutics, Inc. (ALGS) had negative free cash flow of $85.2M in fiscal year 2025, likely due to heavy capital investments.